诺泰生物：与诺唯赞达成战略合作，加码合成生物学产能建设

Core Viewpoint - The strategic cooperation between Nuotai Bio and Nuowei Zhan aims to establish a joint biopharmaceutical company focused on synthetic biology technology, enhancing both companies' capabilities in the field [1][2][3] Group 1: Partnership Details - Nuotai Bio will hold a 51% stake in the joint venture, while Nuowei Zhan will hold 49%, with respective contributions of 45.90% and 44.10% [1] - The partnership will be implemented in two phases, with the first phase focusing on the renovation of existing capacities and the application for DMF of raw materials [1] - The ultimate goal is to establish an annual production capacity of approximately 10 tons of raw materials and corresponding formulations [1] Group 2: Company Strengths - Nuotai Bio is a leading company in the peptide drug sector, having overcome production bottlenecks and achieved industry-leading production levels of over 10 kilograms per batch for drugs like Semaglutide and Aibowei [2] - Nuowei Zhan specializes in the development of functional proteins and high molecular organic materials, holding a leading position in the field of in vitro diagnostic reagents [2] Group 3: Strategic Implications - The collaboration is expected to leverage the strengths of both companies in synthetic biology and peptide drugs, driving product and technology upgrades [3] - The strategic partnership aims to establish an advanced synthetic biology technology platform, promoting interdisciplinary collaboration and industry upgrades [3]